#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=5.
1-1	0-2	5.	abstract	new	_	_

#Text=Conclusions and Perspectives
2-1	3-14	Conclusions	abstract	new	_	_
2-2	15-18	and	_	_	_	_
2-3	19-31	Perspectives	abstract	new	_	_

#Text=EGFR-TKIs are currently the standard first-line treatment of patients with advanced NSCLC with activating EGFR mutations .
3-1	32-41	EGFR-TKIs	abstract	new	coref	3-3[5_0]
3-2	42-45	are	_	_	_	_
3-3	46-55	currently	abstract[5]	giv[5]	coref	7-1[28_5]
3-4	56-59	the	abstract[5]	giv[5]	_	_
3-5	60-68	standard	abstract[5]	giv[5]	_	_
3-6	69-79	first-line	abstract[5]	giv[5]	_	_
3-7	80-89	treatment	abstract[5]	giv[5]	_	_
3-8	90-92	of	abstract[5]	giv[5]	_	_
3-9	93-101	patients	abstract[5]|person[6]	giv[5]|new[6]	coref	15-24[0_6]
3-10	102-106	with	abstract[5]|person[6]	giv[5]|new[6]	_	_
3-11	107-115	advanced	abstract[5]|person[6]|abstract[7]	giv[5]|new[6]|new[7]	coref	10-9[48_7]
3-12	116-121	NSCLC	abstract[5]|person[6]|abstract[7]	giv[5]|new[6]|new[7]	_	_
3-13	122-126	with	abstract[5]|person[6]|abstract[7]	giv[5]|new[6]|new[7]	_	_
3-14	127-137	activating	abstract[5]|person[6]|abstract[7]|abstract[9]	giv[5]|new[6]|new[7]|new[9]	_	_
3-15	138-142	EGFR	abstract[5]|person[6]|abstract[7]|abstract|abstract[9]	giv[5]|new[6]|new[7]|new|new[9]	_	_
3-16	143-152	mutations	abstract[5]|person[6]|abstract[7]|abstract[9]	giv[5]|new[6]|new[7]|new[9]	_	_
3-17	153-154	.	_	_	_	_

#Text=These targeted therapies are usually well tolerated comparative to conventional chemotherapy .
4-1	155-160	These	abstract[10]	new[10]	_	_
4-2	161-169	targeted	abstract[10]	new[10]	_	_
4-3	170-179	therapies	abstract[10]	new[10]	_	_
4-4	180-183	are	_	_	_	_
4-5	184-191	usually	_	_	_	_
4-6	192-196	well	_	_	_	_
4-7	197-206	tolerated	_	_	_	_
4-8	207-218	comparative	_	_	_	_
4-9	219-221	to	_	_	_	_
4-10	222-234	conventional	abstract[11]	new[11]	coref	22-8[147_11]
4-11	235-247	chemotherapy	abstract[11]	new[11]	_	_
4-12	248-249	.	_	_	_	_

#Text=The self-oral administration of the drug positively contributes to improving patient compliance and reducing the use of hospital resources .
5-1	250-253	The	event[12]	new[12]	coref	6-7[0_12]
5-2	254-263	self-oral	event[12]	new[12]	_	_
5-3	264-278	administration	event[12]	new[12]	_	_
5-4	279-281	of	event[12]	new[12]	_	_
5-5	282-285	the	event[12]|substance[13]	new[12]|new[13]	coref	6-18[0_13]
5-6	286-290	drug	event[12]|substance[13]	new[12]|new[13]	_	_
5-7	291-301	positively	_	_	_	_
5-8	302-313	contributes	_	_	_	_
5-9	314-316	to	_	_	_	_
5-10	317-326	improving	_	_	_	_
5-11	327-334	patient	abstract[14]	new[14]	_	_
5-12	335-345	compliance	abstract[14]	new[14]	_	_
5-13	346-349	and	_	_	_	_
5-14	350-358	reducing	_	_	_	_
5-15	359-362	the	abstract[15]	new[15]	coref	20-38[138_15]
5-16	363-366	use	abstract[15]	new[15]	_	_
5-17	367-369	of	abstract[15]	new[15]	_	_
5-18	370-378	hospital	abstract[15]|place|abstract[17]	new[15]|new|new[17]	_	_
5-19	379-388	resources	abstract[15]|abstract[17]	new[15]|new[17]	_	_
5-20	389-390	.	_	_	_	_

#Text=However , this non-invasive route of administration is also associated with unpredictable bioavailability , increased risk of drug interactions , and concerns about patient safety , surveillance , and follow-up .
6-1	391-398	However	_	_	_	_
6-2	399-400	,	_	_	_	_
6-3	401-405	this	abstract[18]	new[18]	_	_
6-4	406-418	non-invasive	abstract[18]	new[18]	_	_
6-5	419-424	route	abstract[18]	new[18]	_	_
6-6	425-427	of	abstract[18]	new[18]	_	_
6-7	428-442	administration	abstract[18]|event	new[18]|giv	_	_
6-8	443-445	is	_	_	_	_
6-9	446-450	also	_	_	_	_
6-10	451-461	associated	_	_	_	_
6-11	462-466	with	_	_	_	_
6-12	467-480	unpredictable	abstract[20]	new[20]	_	_
6-13	481-496	bioavailability	abstract[20]	new[20]	_	_
6-14	497-498	,	_	_	_	_
6-15	499-508	increased	abstract[21]	new[21]	_	_
6-16	509-513	risk	abstract[21]	new[21]	_	_
6-17	514-516	of	abstract[21]	new[21]	_	_
6-18	517-521	drug	abstract[21]|substance|event[23]	new[21]|giv|new[23]	coref	20-22
6-19	522-534	interactions	abstract[21]|event[23]	new[21]|new[23]	_	_
6-20	535-536	,	_	_	_	_
6-21	537-540	and	_	_	_	_
6-22	541-549	concerns	abstract[24]	new[24]	_	_
6-23	550-555	about	abstract[24]	new[24]	_	_
6-24	556-563	patient	abstract[24]|abstract[25]	new[24]|new[25]	_	_
6-25	564-570	safety	abstract[24]|abstract[25]	new[24]|new[25]	_	_
6-26	571-572	,	abstract[24]	new[24]	_	_
6-27	573-585	surveillance	abstract[24]|person	new[24]|new	_	_
6-28	586-587	,	abstract[24]	new[24]	_	_
6-29	588-591	and	abstract[24]	new[24]	_	_
6-30	592-601	follow-up	abstract[24]|event	new[24]|new	coref	11-28[63_0]
6-31	602-603	.	_	_	_	_

#Text=Chronic EGFR-TKIs
7-1	604-611	Chronic	abstract[28]	giv[28]	coref	10-4[0_28]
7-2	612-621	EGFR-TKIs	abstract[28]	giv[28]	_	_

#Text=underdosage may favor the selection of resistant clones and thus disease progression , and overdosage may increase the risk of dose-related side effects .
8-1	622-633	underdosage	abstract	new	_	_
8-2	634-637	may	_	_	_	_
8-3	638-643	favor	_	_	_	_
8-4	644-647	the	event[30]	new[30]	_	_
8-5	648-657	selection	event[30]	new[30]	_	_
8-6	658-660	of	event[30]	new[30]	_	_
8-7	661-670	resistant	event[30]|abstract[31]	new[30]|new[31]	_	_
8-8	671-677	clones	event[30]|abstract[31]	new[30]|new[31]	_	_
8-9	678-681	and	event[30]	new[30]	_	_
8-10	682-686	thus	event[30]|event[33]	new[30]|new[33]	_	_
8-11	687-694	disease	event[30]|abstract|event[33]	new[30]|new|new[33]	coref	10-20[51_0]
8-12	695-706	progression	event[30]|event[33]	new[30]|new[33]	_	_
8-13	707-708	,	_	_	_	_
8-14	709-712	and	_	_	_	_
8-15	713-723	overdosage	event	new	_	_
8-16	724-727	may	_	_	_	_
8-17	728-736	increase	_	_	_	_
8-18	737-740	the	abstract[35]	new[35]	_	_
8-19	741-745	risk	abstract[35]	new[35]	_	_
8-20	746-748	of	abstract[35]	new[35]	_	_
8-21	749-761	dose-related	abstract[35]|abstract[36]	new[35]|new[36]	coref	9-8[39_36]
8-22	762-766	side	abstract[35]|abstract[36]	new[35]|new[36]	_	_
8-23	767-774	effects	abstract[35]|abstract[36]	new[35]|new[36]	_	_
8-24	775-776	.	_	_	_	_

#Text=Self-administration also means that the severity of side effects can be considerably impacted by patient behavior ( e.g. , dietary habits , self-medicating , smoker status ) .
9-1	777-796	Self-administration	abstract	new	_	_
9-2	797-801	also	_	_	_	_
9-3	802-807	means	_	_	_	_
9-4	808-812	that	_	_	_	_
9-5	813-816	the	abstract[38]	new[38]	_	_
9-6	817-825	severity	abstract[38]	new[38]	_	_
9-7	826-828	of	abstract[38]	new[38]	_	_
9-8	829-833	side	abstract[38]|abstract[39]	new[38]|giv[39]	coref	26-32[203_39]
9-9	834-841	effects	abstract[38]|abstract[39]	new[38]|giv[39]	_	_
9-10	842-845	can	_	_	_	_
9-11	846-848	be	_	_	_	_
9-12	849-861	considerably	_	_	_	_
9-13	862-870	impacted	_	_	_	_
9-14	871-873	by	_	_	_	_
9-15	874-881	patient	event[40]	new[40]	_	_
9-16	882-890	behavior	event[40]	new[40]	_	_
9-17	891-892	(	_	_	_	_
9-18	893-897	e.g.	abstract[42]	new[42]	_	_
9-19	898-899	,	abstract[42]	new[42]	_	_
9-20	900-907	dietary	abstract|abstract[42]	new|new[42]	_	_
9-21	908-914	habits	abstract[42]	new[42]	_	_
9-22	915-916	,	_	_	_	_
9-23	917-932	self-medicating	person	new	_	_
9-24	933-934	,	_	_	_	_
9-25	935-941	smoker	person|abstract[45]	new|new[45]	_	_
9-26	942-948	status	abstract[45]	new[45]	_	_
9-27	949-950	)	_	_	_	_
9-28	951-952	.	_	_	_	_

#Text=To date , EGFR-TKIs can be administered in advanced NSCLC for a long period of time , usually until the disease progresses or unacceptable toxicity occurs .
10-1	953-955	To	_	_	_	_
10-2	956-960	date	time	new	_	_
10-3	961-962	,	_	_	_	_
10-4	963-972	EGFR-TKIs	abstract	giv	coref	11-26
10-5	973-976	can	_	_	_	_
10-6	977-979	be	_	_	_	_
10-7	980-992	administered	_	_	_	_
10-8	993-995	in	_	_	_	_
10-9	996-1004	advanced	abstract[48]	giv[48]	coref	29-24[0_48]
10-10	1005-1010	NSCLC	abstract[48]	giv[48]	_	_
10-11	1011-1014	for	_	_	_	_
10-12	1015-1016	a	time[49]	new[49]	_	_
10-13	1017-1021	long	time[49]	new[49]	_	_
10-14	1022-1028	period	time[49]	new[49]	_	_
10-15	1029-1031	of	time[49]	new[49]	_	_
10-16	1032-1036	time	time[49]|abstract	new[49]|new	_	_
10-17	1037-1038	,	_	_	_	_
10-18	1039-1046	usually	_	_	_	_
10-19	1047-1052	until	_	_	_	_
10-20	1053-1056	the	abstract[51]	giv[51]	coref	15-4[0_51]
10-21	1057-1064	disease	abstract[51]	giv[51]	_	_
10-22	1065-1075	progresses	_	_	_	_
10-23	1076-1078	or	_	_	_	_
10-24	1079-1091	unacceptable	abstract[52]	new[52]	coref	11-28[62_52]
10-25	1092-1100	toxicity	abstract[52]	new[52]	_	_
10-26	1101-1107	occurs	_	_	_	_
10-27	1108-1109	.	_	_	_	_

#Text=As early intervention with supportive care strategies can minimize the intensity of adverse reactions or allow for appropriate dose adjustments without the need to discontinue treatment , acute toxicity follow-up and side effect management is of major interest .
11-1	1110-1112	As	_	_	_	_
11-2	1113-1118	early	event[53]	new[53]	_	_
11-3	1119-1131	intervention	event[53]	new[53]	_	_
11-4	1132-1136	with	event[53]	new[53]	_	_
11-5	1137-1147	supportive	event[53]|abstract[55]	new[53]|new[55]	coref	13-4[79_55]
11-6	1148-1152	care	event[53]|abstract|abstract[55]	new[53]|new|new[55]	coref	13-27[86_0]
11-7	1153-1163	strategies	event[53]|abstract[55]	new[53]|new[55]	_	_
11-8	1164-1167	can	_	_	_	_
11-9	1168-1176	minimize	_	_	_	_
11-10	1177-1180	the	abstract[56]	new[56]	_	_
11-11	1181-1190	intensity	abstract[56]	new[56]	_	_
11-12	1191-1193	of	abstract[56]	new[56]	_	_
11-13	1194-1201	adverse	abstract[56]|event[57]	new[56]|new[57]	_	_
11-14	1202-1211	reactions	abstract[56]|event[57]	new[56]|new[57]	_	_
11-15	1212-1214	or	_	_	_	_
11-16	1215-1220	allow	_	_	_	_
11-17	1221-1224	for	_	_	_	_
11-18	1225-1236	appropriate	abstract[59]	new[59]	_	_
11-19	1237-1241	dose	abstract|abstract[59]	new|new[59]	coref	23-20
11-20	1242-1253	adjustments	abstract[59]	new[59]	_	_
11-21	1254-1261	without	_	_	_	_
11-22	1262-1265	the	abstract[60]	new[60]	coref	18-18[117_60]
11-23	1266-1270	need	abstract[60]	new[60]	_	_
11-24	1271-1273	to	abstract[60]	new[60]	_	_
11-25	1274-1285	discontinue	abstract[60]	new[60]	_	_
11-26	1286-1295	treatment	abstract[60]|abstract	new[60]|giv	coref	12-38
11-27	1296-1297	,	_	_	_	_
11-28	1298-1303	acute	abstract[62]|event[63]	giv[62]|giv[63]	coref|coref	16-8[0_62]|21-4[142_63]
11-29	1304-1312	toxicity	abstract[62]|event[63]	giv[62]|giv[63]	_	_
11-30	1313-1322	follow-up	event[63]	giv[63]	_	_
11-31	1323-1326	and	_	_	_	_
11-32	1327-1331	side	abstract|abstract[65]|person[66]	new|new[65]|new[66]	coref	26-33
11-33	1332-1338	effect	abstract[65]|person[66]	new[65]|new[66]	_	_
11-34	1339-1349	management	person[66]	new[66]	_	_
11-35	1350-1352	is	_	_	_	_
11-36	1353-1355	of	_	_	_	_
11-37	1356-1361	major	organization[67]	new[67]	_	_
11-38	1362-1370	interest	organization[67]	new[67]	_	_
11-39	1371-1372	.	_	_	_	_

#Text=Therefore , medical oncologists should not only understand the AEs associated with these drugs , but also develop the necessary skills to detect and treat them to reduce morbidity and mortality as well as premature discontinuation of treatment .
12-1	1373-1382	Therefore	_	_	_	_
12-2	1383-1384	,	_	_	_	_
12-3	1385-1392	medical	person[68]	new[68]	coref	20-3[126_68]
12-4	1393-1404	oncologists	person[68]	new[68]	_	_
12-5	1405-1411	should	_	_	_	_
12-6	1412-1415	not	_	_	_	_
12-7	1416-1420	only	_	_	_	_
12-8	1421-1431	understand	_	_	_	_
12-9	1432-1435	the	abstract[69]	new[69]	coref	18-16[0_69]
12-10	1436-1439	AEs	abstract[69]	new[69]	_	_
12-11	1440-1450	associated	abstract[69]	new[69]	_	_
12-12	1451-1455	with	abstract[69]	new[69]	_	_
12-13	1456-1461	these	abstract[69]|substance[70]	new[69]|new[70]	_	_
12-14	1462-1467	drugs	abstract[69]|substance[70]	new[69]|new[70]	_	_
12-15	1468-1469	,	_	_	_	_
12-16	1470-1473	but	_	_	_	_
12-17	1474-1478	also	_	_	_	_
12-18	1479-1486	develop	_	_	_	_
12-19	1487-1490	the	abstract[71]	new[71]	ana	12-26[0_71]
12-20	1491-1500	necessary	abstract[71]	new[71]	_	_
12-21	1501-1507	skills	abstract[71]	new[71]	_	_
12-22	1508-1510	to	abstract[71]	new[71]	_	_
12-23	1511-1517	detect	abstract[71]	new[71]	_	_
12-24	1518-1521	and	abstract[71]	new[71]	_	_
12-25	1522-1527	treat	abstract[71]	new[71]	_	_
12-26	1528-1532	them	abstract[71]|abstract	new[71]|giv	_	_
12-27	1533-1535	to	_	_	_	_
12-28	1536-1542	reduce	_	_	_	_
12-29	1543-1552	morbidity	abstract	new	_	_
12-30	1553-1556	and	_	_	_	_
12-31	1557-1566	mortality	abstract	new	_	_
12-32	1567-1569	as	_	_	_	_
12-33	1570-1574	well	_	_	_	_
12-34	1575-1577	as	_	_	_	_
12-35	1578-1587	premature	event[75]	new[75]	coref	25-27[0_75]
12-36	1588-1603	discontinuation	event[75]	new[75]	_	_
12-37	1604-1606	of	event[75]	new[75]	_	_
12-38	1607-1616	treatment	event[75]|abstract	new[75]|giv	coref	13-23
12-39	1617-1618	.	_	_	_	_

#Text=Patient education on these strategies is also of major importance and can improve patient tolerance , quality of life , and overall treatment outcome by initiating supportive care soon after symptoms occur .
13-1	1619-1626	Patient	person|abstract[78]	new|new[78]	coref|coref	20-11[128_78]|21-5
13-2	1627-1636	education	abstract[78]	new[78]	_	_
13-3	1637-1639	on	abstract[78]	new[78]	_	_
13-4	1640-1645	these	abstract[78]|abstract[79]	new[78]|giv[79]	coref	19-19[125_79]
13-5	1646-1656	strategies	abstract[78]|abstract[79]	new[78]|giv[79]	_	_
13-6	1657-1659	is	_	_	_	_
13-7	1660-1664	also	_	_	_	_
13-8	1665-1667	of	_	_	_	_
13-9	1668-1673	major	abstract[80]	new[80]	coref	21-1[140_80]
13-10	1674-1684	importance	abstract[80]	new[80]	_	_
13-11	1685-1688	and	_	_	_	_
13-12	1689-1692	can	_	_	_	_
13-13	1693-1700	improve	_	_	_	_
13-14	1701-1708	patient	abstract[81]	new[81]	_	_
13-15	1709-1718	tolerance	abstract[81]	new[81]	_	_
13-16	1719-1720	,	_	_	_	_
13-17	1721-1728	quality	abstract[82]	new[82]	_	_
13-18	1729-1731	of	abstract[82]	new[82]	_	_
13-19	1732-1736	life	abstract[82]|abstract	new[82]|new	coref	22-27
13-20	1737-1738	,	_	_	_	_
13-21	1739-1742	and	_	_	_	_
13-22	1743-1750	overall	abstract[85]	new[85]	_	_
13-23	1751-1760	treatment	abstract|abstract[85]	giv|new[85]	coref	15-17
13-24	1761-1768	outcome	abstract[85]	new[85]	_	_
13-25	1769-1771	by	_	_	_	_
13-26	1772-1782	initiating	_	_	_	_
13-27	1783-1793	supportive	abstract[86]	giv[86]	coref	29-18[232_86]
13-28	1794-1798	care	abstract[86]	giv[86]	_	_
13-29	1799-1803	soon	_	_	_	_
13-30	1804-1809	after	_	_	_	_
13-31	1810-1818	symptoms	abstract	new	_	_
13-32	1819-1824	occur	_	_	_	_
13-33	1825-1826	.	_	_	_	_

#Text=Within this guidance and preventive strategy , the pharmacist can play a major role .
14-1	1827-1833	Within	_	_	_	_
14-2	1834-1838	this	abstract[88]	new[88]	_	_
14-3	1839-1847	guidance	abstract[88]	new[88]	_	_
14-4	1848-1851	and	_	_	_	_
14-5	1852-1862	preventive	abstract[89]	new[89]	_	_
14-6	1863-1871	strategy	abstract[89]	new[89]	_	_
14-7	1872-1873	,	_	_	_	_
14-8	1874-1877	the	person[90]	new[90]	_	_
14-9	1878-1888	pharmacist	person[90]	new[90]	_	_
14-10	1889-1892	can	_	_	_	_
14-11	1893-1897	play	_	_	_	_
14-12	1898-1899	a	abstract[91]	new[91]	_	_
14-13	1900-1905	major	abstract[91]	new[91]	_	_
14-14	1906-1910	role	abstract[91]	new[91]	_	_
14-15	1911-1912	.	_	_	_	_

#Text=Good knowledge of disease monitoring , response milestones , and the risks versus benefits of the treatment options allows pharmacists to better advise patients or counsel patients more effectively .
15-1	1913-1917	Good	abstract[92]	new[92]	_	_
15-2	1918-1927	knowledge	abstract[92]	new[92]	_	_
15-3	1928-1930	of	abstract[92]	new[92]	_	_
15-4	1931-1938	disease	abstract[92]|abstract|event[94]	new[92]|giv|new[94]	coref|coref	20-22[132_94]|28-25
15-5	1939-1949	monitoring	abstract[92]|event[94]	new[92]|new[94]	_	_
15-6	1950-1951	,	abstract[92]	new[92]	_	_
15-7	1952-1960	response	abstract[92]|abstract|event[96]	new[92]|new|new[96]	coref	28-25[220_0]
15-8	1961-1971	milestones	abstract[92]|event[96]	new[92]|new[96]	_	_
15-9	1972-1973	,	_	_	_	_
15-10	1974-1977	and	_	_	_	_
15-11	1978-1981	the	abstract[97]	new[97]	coref	16-8[108_97]
15-12	1982-1987	risks	abstract[97]	new[97]	_	_
15-13	1988-1994	versus	_	_	_	_
15-14	1995-2003	benefits	abstract[98]	new[98]	_	_
15-15	2004-2006	of	abstract[98]	new[98]	_	_
15-16	2007-2010	the	abstract[98]|abstract[100]	new[98]|new[100]	_	_
15-17	2011-2020	treatment	abstract[98]|abstract|abstract[100]	new[98]|giv|new[100]	_	_
15-18	2021-2028	options	abstract[98]|abstract[100]	new[98]|new[100]	_	_
15-19	2029-2035	allows	_	_	_	_
15-20	2036-2047	pharmacists	person	new	coref	18-5[112_0]
15-21	2048-2050	to	_	_	_	_
15-22	2051-2057	better	_	_	_	_
15-23	2058-2064	advise	_	_	_	_
15-24	2065-2073	patients	person	giv	coref	15-27
15-25	2074-2076	or	_	_	_	_
15-26	2077-2084	counsel	_	_	_	_
15-27	2085-2093	patients	person	giv	coref	18-1
15-28	2094-2098	more	_	_	_	_
15-29	2099-2110	effectively	_	_	_	_
15-30	2111-2112	.	_	_	_	_

#Text=Nurses and prescribers are qualified to monitor toxicity risks as closely as possible .
16-1	2113-2119	Nurses	person|person[105]	new|new[105]	coref|coref	19-14|19-14[123_105]
16-2	2120-2123	and	person[105]	new[105]	_	_
16-3	2124-2135	prescribers	person[105]|person	new[105]|new	ana	17-3
16-4	2136-2139	are	_	_	_	_
16-5	2140-2149	qualified	_	_	_	_
16-6	2150-2152	to	_	_	_	_
16-7	2153-2160	monitor	_	_	_	_
16-8	2161-2169	toxicity	abstract|abstract[108]	giv|giv[108]	_	_
16-9	2170-2175	risks	abstract[108]	giv[108]	_	_
16-10	2176-2178	as	_	_	_	_
16-11	2179-2186	closely	_	_	_	_
16-12	2187-2189	as	_	_	_	_
16-13	2190-2198	possible	_	_	_	_
16-14	2199-2200	.	_	_	_	_

#Text=Unfortunately , they do not necessarily do so at regular intervals .
17-1	2201-2214	Unfortunately	_	_	_	_
17-2	2215-2216	,	_	_	_	_
17-3	2217-2221	they	person	giv	coref	18-25
17-4	2222-2224	do	_	_	_	_
17-5	2225-2228	not	_	_	_	_
17-6	2229-2240	necessarily	_	_	_	_
17-7	2241-2243	do	_	_	_	_
17-8	2244-2246	so	_	_	_	_
17-9	2247-2249	at	_	_	_	_
17-10	2250-2257	regular	time[110]	new[110]	_	_
17-11	2258-2267	intervals	time[110]	new[110]	_	_
17-12	2268-2269	.	_	_	_	_

#Text=Patients can connect with pharmacists who can provide them additional information or complementary recommendations on AEs without the need for patients to rapidly contact prescribers .
18-1	2270-2278	Patients	person	giv	coref	18-21
18-2	2279-2282	can	_	_	_	_
18-3	2283-2290	connect	_	_	_	_
18-4	2291-2295	with	_	_	_	_
18-5	2296-2307	pharmacists	person[112]	giv[112]	ana	18-9[0_112]
18-6	2308-2311	who	person[112]	giv[112]	_	_
18-7	2312-2315	can	person[112]	giv[112]	_	_
18-8	2316-2323	provide	person[112]	giv[112]	_	_
18-9	2324-2328	them	person[112]|person	giv[112]|giv	coref	19-9[121_0]
18-10	2329-2339	additional	person[112]|abstract[114]	giv[112]|new[114]	_	_
18-11	2340-2351	information	person[112]|abstract[114]	giv[112]|new[114]	_	_
18-12	2352-2354	or	person[112]	giv[112]	_	_
18-13	2355-2368	complementary	person[112]|abstract[115]	giv[112]|new[115]	_	_
18-14	2369-2384	recommendations	person[112]|abstract[115]	giv[112]|new[115]	_	_
18-15	2385-2387	on	person[112]|abstract[115]	giv[112]|new[115]	_	_
18-16	2388-2391	AEs	person[112]|abstract[115]|abstract	giv[112]|new[115]|giv	coref	19-2[120_0]
18-17	2392-2399	without	person[112]	giv[112]	_	_
18-18	2400-2403	the	person[112]|abstract[117]	giv[112]|giv[117]	_	_
18-19	2404-2408	need	person[112]|abstract[117]	giv[112]|giv[117]	_	_
18-20	2409-2412	for	person[112]|abstract[117]	giv[112]|giv[117]	_	_
18-21	2413-2421	patients	person[112]|abstract[117]|person	giv[112]|giv[117]|giv	coref	22-6[146_0]
18-22	2422-2424	to	person[112]|abstract[117]	giv[112]|giv[117]	_	_
18-23	2425-2432	rapidly	person[112]|abstract[117]	giv[112]|giv[117]	_	_
18-24	2433-2440	contact	person[112]|abstract[117]	giv[112]|giv[117]	_	_
18-25	2441-2452	prescribers	person[112]|abstract[117]|person	giv[112]|giv[117]|giv	coref	19-16
18-26	2453-2454	.	_	_	_	_

#Text=When more complex or serious AEs appear , pharmacists who work closely with nurses and prescribers can propose the most appropriate therapeutic strategies .
19-1	2455-2459	When	_	_	_	_
19-2	2460-2464	more	abstract[120]	giv[120]	coref	20-8[0_120]
19-3	2465-2472	complex	abstract[120]	giv[120]	_	_
19-4	2473-2475	or	abstract[120]	giv[120]	_	_
19-5	2476-2483	serious	abstract[120]	giv[120]	_	_
19-6	2484-2487	AEs	abstract[120]	giv[120]	_	_
19-7	2488-2494	appear	_	_	_	_
19-8	2495-2496	,	_	_	_	_
19-9	2497-2508	pharmacists	person[121]	giv[121]	_	_
19-10	2509-2512	who	person[121]	giv[121]	_	_
19-11	2513-2517	work	person[121]	giv[121]	_	_
19-12	2518-2525	closely	person[121]	giv[121]	_	_
19-13	2526-2530	with	person[121]	giv[121]	_	_
19-14	2531-2537	nurses	person[121]|person|person[123]	giv[121]|giv|giv[123]	coref	29-11
19-15	2538-2541	and	person[121]|person[123]	giv[121]|giv[123]	_	_
19-16	2542-2553	prescribers	person[121]|person[123]|person	giv[121]|giv[123]|giv	_	_
19-17	2554-2557	can	_	_	_	_
19-18	2558-2565	propose	_	_	_	_
19-19	2566-2569	the	abstract[125]	giv[125]	_	_
19-20	2570-2574	most	abstract[125]	giv[125]	_	_
19-21	2575-2586	appropriate	abstract[125]	giv[125]	_	_
19-22	2587-2598	therapeutic	abstract[125]	giv[125]	_	_
19-23	2599-2609	strategies	abstract[125]	giv[125]	_	_
19-24	2610-2611	.	_	_	_	_

#Text=Finally , medical oncologists able to understand AEs along with patient education and collaboration between different medical professional groups for therapeutic drug monitoring systems are needed , but further research on the aforementioned methods of relief for continued TKI use should be also performed in the future .
20-1	2612-2619	Finally	_	_	_	_
20-2	2620-2621	,	_	_	_	_
20-3	2622-2629	medical	person[126]	giv[126]	coref	29-4[0_126]
20-4	2630-2641	oncologists	person[126]	giv[126]	_	_
20-5	2642-2646	able	person[126]	giv[126]	_	_
20-6	2647-2649	to	person[126]	giv[126]	_	_
20-7	2650-2660	understand	person[126]	giv[126]	_	_
20-8	2661-2664	AEs	person[126]|abstract	giv[126]|giv	coref	23-29[170_0]
20-9	2665-2670	along	person[126]	giv[126]	_	_
20-10	2671-2675	with	_	_	_	_
20-11	2676-2683	patient	abstract[128]	giv[128]	coref	28-9[212_128]
20-12	2684-2693	education	abstract[128]	giv[128]	_	_
20-13	2694-2697	and	_	_	_	_
20-14	2698-2711	collaboration	abstract[129]	new[129]	_	_
20-15	2712-2719	between	abstract[129]	new[129]	_	_
20-16	2720-2729	different	abstract[129]|organization[130]	new[129]|new[130]	_	_
20-17	2730-2737	medical	abstract[129]|organization[130]	new[129]|new[130]	_	_
20-18	2738-2750	professional	abstract[129]|organization[130]	new[129]|new[130]	_	_
20-19	2751-2757	groups	abstract[129]|organization[130]	new[129]|new[130]	_	_
20-20	2758-2761	for	abstract[129]	new[129]	_	_
20-21	2762-2773	therapeutic	abstract[129]|abstract[133]	new[129]|new[133]	_	_
20-22	2774-2778	drug	abstract[129]|substance|event[132]|abstract[133]	new[129]|giv|giv[132]|new[133]	coref|coref	28-9|28-23[0_132]
20-23	2779-2789	monitoring	abstract[129]|event[132]|abstract[133]	new[129]|giv[132]|new[133]	_	_
20-24	2790-2797	systems	abstract[129]|abstract[133]	new[129]|new[133]	_	_
20-25	2798-2801	are	_	_	_	_
20-26	2802-2808	needed	_	_	_	_
20-27	2809-2810	,	_	_	_	_
20-28	2811-2814	but	_	_	_	_
20-29	2815-2822	further	abstract[134]	new[134]	_	_
20-30	2823-2831	research	abstract[134]	new[134]	_	_
20-31	2832-2834	on	abstract[134]	new[134]	_	_
20-32	2835-2838	the	abstract[134]|abstract[135]	new[134]|new[135]	_	_
20-33	2839-2853	aforementioned	abstract[134]|abstract[135]	new[134]|new[135]	_	_
20-34	2854-2861	methods	abstract[134]|abstract[135]	new[134]|new[135]	_	_
20-35	2862-2864	of	abstract[134]|abstract[135]	new[134]|new[135]	_	_
20-36	2865-2871	relief	abstract[134]|abstract[135]|abstract	new[134]|new[135]|new	_	_
20-37	2872-2875	for	abstract[134]|abstract[135]	new[134]|new[135]	_	_
20-38	2876-2885	continued	abstract[134]|abstract[135]|abstract[138]	new[134]|new[135]|giv[138]	_	_
20-39	2886-2889	TKI	abstract[134]|abstract[135]|place|abstract[138]	new[134]|new[135]|new|giv[138]	_	_
20-40	2890-2893	use	abstract[134]|abstract[135]|abstract[138]	new[134]|new[135]|giv[138]	_	_
20-41	2894-2900	should	_	_	_	_
20-42	2901-2903	be	_	_	_	_
20-43	2904-2908	also	_	_	_	_
20-44	2909-2918	performed	_	_	_	_
20-45	2919-2921	in	_	_	_	_
20-46	2922-2925	the	time[139]	new[139]	_	_
20-47	2926-2932	future	time[139]	new[139]	_	_
20-48	2933-2934	.	_	_	_	_

#Text=The importance of proactive patient follow-up must be emphasized rather than relying on self-reporting between clinical visits .
21-1	2935-2938	The	abstract[140]	giv[140]	_	_
21-2	2939-2949	importance	abstract[140]	giv[140]	_	_
21-3	2950-2952	of	abstract[140]	giv[140]	_	_
21-4	2953-2962	proactive	abstract[140]|event[142]	giv[140]|giv[142]	coref	23-14[0_142]
21-5	2963-2970	patient	abstract[140]|person|event[142]	giv[140]|giv|giv[142]	coref	28-6
21-6	2971-2980	follow-up	abstract[140]|event[142]	giv[140]|giv[142]	_	_
21-7	2981-2985	must	_	_	_	_
21-8	2986-2988	be	_	_	_	_
21-9	2989-2999	emphasized	_	_	_	_
21-10	3000-3006	rather	_	_	_	_
21-11	3007-3011	than	_	_	_	_
21-12	3012-3019	relying	_	_	_	_
21-13	3020-3022	on	_	_	_	_
21-14	3023-3037	self-reporting	abstract[143]	new[143]	_	_
21-15	3038-3045	between	abstract[143]	new[143]	_	_
21-16	3046-3054	clinical	abstract[143]|event[144]	new[143]|new[144]	coref	22-29[158_144]
21-17	3055-3061	visits	abstract[143]|event[144]	new[143]|new[144]	_	_
21-18	3062-3063	.	_	_	_	_

#Text=A randomized trial showed that patients receiving chemotherapy for advanced cancer , web-based symptom reporting with automated clinician e-mail alerts resulted in better health-related quality of life , fewer emergency room visits , fewer hospitalizations , and superior quality-adjusted survival .
22-1	3064-3065	A	abstract[145]	new[145]	_	_
22-2	3066-3076	randomized	abstract[145]	new[145]	_	_
22-3	3077-3082	trial	abstract[145]	new[145]	_	_
22-4	3083-3089	showed	_	_	_	_
22-5	3090-3094	that	_	_	_	_
22-6	3095-3103	patients	person[146]	giv[146]	coref	23-31[171_146]
22-7	3104-3113	receiving	person[146]	giv[146]	_	_
22-8	3114-3126	chemotherapy	person[146]|abstract[147]	giv[146]|giv[147]	_	_
22-9	3127-3130	for	person[146]|abstract[147]	giv[146]|giv[147]	_	_
22-10	3131-3139	advanced	person[146]|abstract[147]|abstract[148]	giv[146]|giv[147]|new[148]	_	_
22-11	3140-3146	cancer	person[146]|abstract[147]|abstract[148]	giv[146]|giv[147]|new[148]	_	_
22-12	3147-3148	,	_	_	_	_
22-13	3149-3158	web-based	abstract[150]	new[150]	_	_
22-14	3159-3166	symptom	abstract|abstract[150]	new|new[150]	_	_
22-15	3167-3176	reporting	abstract[150]	new[150]	_	_
22-16	3177-3181	with	abstract[150]	new[150]	_	_
22-17	3182-3191	automated	abstract[150]|abstract[153]	new[150]|new[153]	_	_
22-18	3192-3201	clinician	abstract[150]|person|abstract[153]	new[150]|new|new[153]	coref	28-4
22-19	3202-3208	e-mail	abstract[150]|abstract|abstract[153]	new[150]|new|new[153]	_	_
22-20	3209-3215	alerts	abstract[150]|abstract[153]	new[150]|new[153]	_	_
22-21	3216-3224	resulted	_	_	_	_
22-22	3225-3227	in	_	_	_	_
22-23	3228-3234	better	abstract[154]	new[154]	_	_
22-24	3235-3249	health-related	abstract[154]	new[154]	_	_
22-25	3250-3257	quality	abstract[154]	new[154]	_	_
22-26	3258-3260	of	abstract[154]	new[154]	_	_
22-27	3261-3265	life	abstract[154]|abstract	new[154]|giv	_	_
22-28	3266-3267	,	_	_	_	_
22-29	3268-3273	fewer	event[158]	giv[158]	coref	25-15[187_158]
22-30	3274-3283	emergency	abstract|place[157]|event[158]	new|new[157]|giv[158]	coref|coref	25-12|25-11[185_157]
22-31	3284-3288	room	place[157]|event[158]	new[157]|giv[158]	_	_
22-32	3289-3295	visits	event[158]	giv[158]	_	_
22-33	3296-3297	,	_	_	_	_
22-34	3298-3303	fewer	place[159]	new[159]	_	_
22-35	3304-3320	hospitalizations	place[159]	new[159]	_	_
22-36	3321-3322	,	_	_	_	_
22-37	3323-3326	and	_	_	_	_
22-38	3327-3335	superior	event[160]	new[160]	coref	27-7[205_160]
22-39	3336-3352	quality-adjusted	event[160]	new[160]	_	_
22-40	3353-3361	survival	event[160]	new[160]	_	_
22-41	3362-3363	.	_	_	_	_

#Text=Recently , Cheema et al. assessed the impact of an interprofessional , proactive follow-up algorithm on the incidence of dose interruptions , reductions , and the severity of AEs in patients on afatinib .
23-1	3364-3372	Recently	_	_	_	_
23-2	3373-3374	,	_	_	_	_
23-3	3375-3381	Cheema	person	new	_	_
23-4	3382-3384	et	_	_	_	_
23-5	3385-3388	al.	_	_	_	_
23-6	3389-3397	assessed	_	_	_	_
23-7	3398-3401	the	abstract[162]	new[162]	_	_
23-8	3402-3408	impact	abstract[162]	new[162]	_	_
23-9	3409-3411	of	abstract[162]	new[162]	_	_
23-10	3412-3414	an	abstract[162]|abstract[164]	new[162]|new[164]	coref	25-1[182_164]
23-11	3415-3432	interprofessional	abstract[162]|abstract[164]	new[162]|new[164]	_	_
23-12	3433-3434	,	abstract[162]|abstract[164]	new[162]|new[164]	_	_
23-13	3435-3444	proactive	abstract[162]|abstract[164]	new[162]|new[164]	_	_
23-14	3445-3454	follow-up	abstract[162]|event|abstract[164]	new[162]|giv|new[164]	coref	24-24[180_0]
23-15	3455-3464	algorithm	abstract[162]|abstract[164]	new[162]|new[164]	_	_
23-16	3465-3467	on	abstract[162]	new[162]	_	_
23-17	3468-3471	the	abstract[162]|abstract[165]	new[162]|new[165]	_	_
23-18	3472-3481	incidence	abstract[162]|abstract[165]	new[162]|new[165]	_	_
23-19	3482-3484	of	abstract[162]|abstract[165]	new[162]|new[165]	_	_
23-20	3485-3489	dose	abstract[162]|abstract[165]|abstract|abstract[167]	new[162]|new[165]|giv|new[167]	_	_
23-21	3490-3503	interruptions	abstract[162]|abstract[165]|abstract[167]	new[162]|new[165]|new[167]	_	_
23-22	3504-3505	,	abstract[162]|abstract[165]	new[162]|new[165]	_	_
23-23	3506-3516	reductions	abstract[162]|abstract[165]|abstract	new[162]|new[165]|new	_	_
23-24	3517-3518	,	abstract[162]|abstract[165]	new[162]|new[165]	_	_
23-25	3519-3522	and	abstract[162]|abstract[165]	new[162]|new[165]	_	_
23-26	3523-3526	the	abstract[162]|abstract[165]|abstract[169]	new[162]|new[165]|new[169]	_	_
23-27	3527-3535	severity	abstract[162]|abstract[165]|abstract[169]	new[162]|new[165]|new[169]	_	_
23-28	3536-3538	of	abstract[162]|abstract[165]|abstract[169]	new[162]|new[165]|new[169]	_	_
23-29	3539-3542	AEs	abstract[162]|abstract[165]|abstract[169]|abstract[170]	new[162]|new[165]|new[169]|giv[170]	coref	24-8[175_170]
23-30	3543-3545	in	abstract[162]|abstract[165]|abstract[169]|abstract[170]	new[162]|new[165]|new[169]|giv[170]	_	_
23-31	3546-3554	patients	abstract[162]|abstract[165]|abstract[169]|abstract[170]|person[171]	new[162]|new[165]|new[169]|giv[170]|giv[171]	coref	26-7[0_171]
23-32	3555-3557	on	abstract[162]|abstract[165]|abstract[169]|abstract[170]|person[171]	new[162]|new[165]|new[169]|giv[170]|giv[171]	_	_
23-33	3558-3566	afatinib	abstract[162]|abstract[165]|abstract[169]|abstract[170]|person[171]|substance	new[162]|new[165]|new[169]|giv[170]|giv[171]|new	_	_
23-34	3567-3568	.	_	_	_	_

#Text=The authors reported that over half of first AEs and one third of all grade 1-2 and grade ≥3 AEs were detected through proactive follow-up .
24-1	3569-3572	The	person[173]	new[173]	_	_
24-2	3573-3580	authors	person[173]	new[173]	_	_
24-3	3581-3589	reported	_	_	_	_
24-4	3590-3594	that	_	_	_	_
24-5	3595-3599	over	_	_	_	_
24-6	3600-3604	half	abstract[174]	new[174]	_	_
24-7	3605-3607	of	abstract[174]	new[174]	_	_
24-8	3608-3613	first	abstract[174]|abstract[175]	new[174]|giv[175]	coref	24-14[179_175]
24-9	3614-3617	AEs	abstract[174]|abstract[175]	new[174]|giv[175]	_	_
24-10	3618-3621	and	_	_	_	_
24-11	3622-3625	one	abstract[176]	new[176]	_	_
24-12	3626-3631	third	abstract[176]	new[176]	_	_
24-13	3632-3634	of	abstract[176]	new[176]	_	_
24-14	3635-3638	all	abstract[176]|abstract[179]	new[176]|giv[179]	coref	25-23[189_179]
24-15	3639-3644	grade	abstract[176]|abstract|abstract[179]	new[176]|new|giv[179]	coref	24-18[178_0]
24-16	3645-3648	1-2	abstract[176]|abstract[179]	new[176]|giv[179]	_	_
24-17	3649-3652	and	abstract[176]|abstract[179]	new[176]|giv[179]	_	_
24-18	3653-3658	grade	abstract[176]|abstract[178]|abstract[179]	new[176]|giv[178]|giv[179]	_	_
24-19	3659-3661	≥3	abstract[176]|abstract[178]|abstract[179]	new[176]|giv[178]|giv[179]	_	_
24-20	3662-3665	AEs	abstract[176]|abstract[179]	new[176]|giv[179]	_	_
24-21	3666-3670	were	_	_	_	_
24-22	3671-3679	detected	_	_	_	_
24-23	3680-3687	through	_	_	_	_
24-24	3688-3697	proactive	event[180]	giv[180]	coref	26-19[197_180]
24-25	3698-3707	follow-up	event[180]	giv[180]	_	_
24-26	3708-3709	.	_	_	_	_

#Text=This multi-disciplinary AE algorithm resulted in a low rate of costly emergency room or urgent clinic visits and a reduced incidence of severe drug-related AEs and discontinuation therapy .
25-1	3710-3714	This	abstract[182]	giv[182]	_	_
25-2	3715-3733	multi-disciplinary	abstract[182]	giv[182]	_	_
25-3	3734-3736	AE	abstract|abstract[182]	new|giv[182]	_	_
25-4	3737-3746	algorithm	abstract[182]	giv[182]	_	_
25-5	3747-3755	resulted	_	_	_	_
25-6	3756-3758	in	_	_	_	_
25-7	3759-3760	a	abstract[183]	new[183]	_	_
25-8	3761-3764	low	abstract[183]	new[183]	_	_
25-9	3765-3769	rate	abstract[183]	new[183]	_	_
25-10	3770-3772	of	abstract[183]	new[183]	_	_
25-11	3773-3779	costly	abstract[183]|place[185]	new[183]|giv[185]	_	_
25-12	3780-3789	emergency	abstract[183]|abstract|place[185]	new[183]|giv|giv[185]	_	_
25-13	3790-3794	room	abstract[183]|place[185]	new[183]|giv[185]	_	_
25-14	3795-3797	or	abstract[183]	new[183]	_	_
25-15	3798-3804	urgent	abstract[183]|place[186]|event[187]	new[183]|new[186]|giv[187]	_	_
25-16	3805-3811	clinic	abstract[183]|place[186]|event[187]	new[183]|new[186]|giv[187]	_	_
25-17	3812-3818	visits	abstract[183]|event[187]	new[183]|giv[187]	_	_
25-18	3819-3822	and	_	_	_	_
25-19	3823-3824	a	abstract[188]	new[188]	_	_
25-20	3825-3832	reduced	abstract[188]	new[188]	_	_
25-21	3833-3842	incidence	abstract[188]	new[188]	_	_
25-22	3843-3845	of	abstract[188]	new[188]	_	_
25-23	3846-3852	severe	abstract[188]|abstract[189]|abstract[190]	new[188]|giv[189]|giv[190]	coref	25-23[190_189]
25-24	3853-3865	drug-related	abstract[188]|abstract[189]|abstract[190]	new[188]|giv[189]|giv[190]	_	_
25-25	3866-3869	AEs	abstract[188]|abstract[189]|abstract[190]	new[188]|giv[189]|giv[190]	_	_
25-26	3870-3873	and	abstract[188]|abstract[190]	new[188]|giv[190]	_	_
25-27	3874-3889	discontinuation	abstract[188]|abstract[190]|event|abstract[192]	new[188]|giv[190]|giv|new[192]	_	_
25-28	3890-3897	therapy	abstract[188]|abstract[190]|abstract[192]	new[188]|giv[190]|new[192]	_	_
25-29	3898-3899	.	_	_	_	_

#Text=In conclusion , when closely monitoring patients , the ability of clinicians to make rapid therapeutic decisions in the event of medical complications is critical in the diagnosis and management of TKI-related side effects .
26-1	3900-3902	In	_	_	_	_
26-2	3903-3913	conclusion	_	_	_	_
26-3	3914-3915	,	_	_	_	_
26-4	3916-3920	when	_	_	_	_
26-5	3921-3928	closely	_	_	_	_
26-6	3929-3939	monitoring	_	_	_	_
26-7	3940-3948	patients	person	giv	coref	29-23[234_0]
26-8	3949-3950	,	_	_	_	_
26-9	3951-3954	the	abstract[194]	new[194]	_	_
26-10	3955-3962	ability	abstract[194]	new[194]	_	_
26-11	3963-3965	of	abstract[194]	new[194]	_	_
26-12	3966-3976	clinicians	abstract[194]|person[195]	new[194]|new[195]	_	_
26-13	3977-3979	to	abstract[194]|person[195]	new[194]|new[195]	_	_
26-14	3980-3984	make	abstract[194]|person[195]	new[194]|new[195]	_	_
26-15	3985-3990	rapid	abstract[194]|person[195]|abstract[196]	new[194]|new[195]|new[196]	_	_
26-16	3991-4002	therapeutic	abstract[194]|person[195]|abstract[196]	new[194]|new[195]|new[196]	_	_
26-17	4003-4012	decisions	abstract[194]|person[195]|abstract[196]	new[194]|new[195]|new[196]	_	_
26-18	4013-4015	in	abstract[194]|person[195]	new[194]|new[195]	_	_
26-19	4016-4019	the	abstract[194]|person[195]|event[197]	new[194]|new[195]|giv[197]	_	_
26-20	4020-4025	event	abstract[194]|person[195]|event[197]	new[194]|new[195]|giv[197]	_	_
26-21	4026-4028	of	abstract[194]|person[195]|event[197]	new[194]|new[195]|giv[197]	_	_
26-22	4029-4036	medical	abstract[194]|person[195]|event[197]|abstract[198]	new[194]|new[195]|giv[197]|new[198]	coref	27-10[206_198]
26-23	4037-4050	complications	abstract[194]|person[195]|event[197]|abstract[198]	new[194]|new[195]|giv[197]|new[198]	_	_
26-24	4051-4053	is	_	_	_	_
26-25	4054-4062	critical	_	_	_	_
26-26	4063-4065	in	_	_	_	_
26-27	4066-4069	the	abstract[199]	new[199]	ana	27-1[0_199]
26-28	4070-4079	diagnosis	abstract[199]	new[199]	_	_
26-29	4080-4083	and	_	_	_	_
26-30	4084-4094	management	organization[200]	new[200]	_	_
26-31	4095-4097	of	organization[200]	new[200]	_	_
26-32	4098-4109	TKI-related	organization[200]|abstract|abstract[203]	new[200]|new|giv[203]	coref	28-18[217_203]
26-33	4110-4114	side	organization[200]|abstract|abstract[203]	new[200]|giv|giv[203]	coref	28-19
26-34	4115-4122	effects	organization[200]|abstract[203]	new[200]|giv[203]	_	_
26-35	4123-4124	.	_	_	_	_

#Text=This is even more decisive in the event of serious or even life-threatening complications .
27-1	4125-4129	This	abstract	giv	_	_
27-2	4130-4132	is	_	_	_	_
27-3	4133-4137	even	_	_	_	_
27-4	4138-4142	more	_	_	_	_
27-5	4143-4151	decisive	_	_	_	_
27-6	4152-4154	in	_	_	_	_
27-7	4155-4158	the	event[205]	giv[205]	_	_
27-8	4159-4164	event	event[205]	giv[205]	_	_
27-9	4165-4167	of	event[205]	giv[205]	_	_
27-10	4168-4175	serious	event[205]|abstract[206]	giv[205]|giv[206]	_	_
27-11	4176-4178	or	event[205]|abstract[206]	giv[205]|giv[206]	_	_
27-12	4179-4183	even	event[205]|abstract[206]	giv[205]|giv[206]	_	_
27-13	4184-4200	life-threatening	event[205]|abstract[206]	giv[205]|giv[206]	_	_
27-14	4201-4214	complications	event[205]|abstract[206]	giv[205]|giv[206]	_	_
27-15	4215-4216	.	_	_	_	_

#Text=However , good clinician – patient communication , drug patient education , early detection and management of drug side effects , and monitoring of disease response with plasma concentration quantification can also improve patient outcomes .
28-1	4217-4224	However	_	_	_	_
28-2	4225-4226	,	_	_	_	_
28-3	4227-4231	good	abstract[209]	new[209]	_	_
28-4	4232-4241	clinician	person|abstract[209]	giv|new[209]	_	_
28-5	4242-4243	–	abstract[209]	new[209]	_	_
28-6	4244-4251	patient	person|abstract[209]	giv|new[209]	coref	28-10
28-7	4252-4265	communication	abstract[209]	new[209]	_	_
28-8	4266-4267	,	_	_	_	_
28-9	4268-4272	drug	substance|abstract[212]	giv|giv[212]	coref	28-18
28-10	4273-4280	patient	person|abstract[212]	giv|giv[212]	coref	28-34
28-11	4281-4290	education	abstract[212]	giv[212]	_	_
28-12	4291-4292	,	_	_	_	_
28-13	4293-4298	early	abstract[213]	new[213]	_	_
28-14	4299-4308	detection	abstract[213]	new[213]	_	_
28-15	4309-4312	and	_	_	_	_
28-16	4313-4323	management	organization[214]	new[214]	_	_
28-17	4324-4326	of	organization[214]	new[214]	_	_
28-18	4327-4331	drug	organization[214]|substance|abstract[217]	new[214]|giv|giv[217]	_	_
28-19	4332-4336	side	organization[214]|abstract|abstract[217]	new[214]|giv|giv[217]	_	_
28-20	4337-4344	effects	organization[214]|abstract[217]	new[214]|giv[217]	_	_
28-21	4345-4346	,	organization[214]	new[214]	_	_
28-22	4347-4350	and	organization[214]	new[214]	_	_
28-23	4351-4361	monitoring	organization[214]|event	new[214]|giv	_	_
28-24	4362-4364	of	organization[214]	new[214]	_	_
28-25	4365-4372	disease	organization[214]|abstract|abstract[220]	new[214]|giv|giv[220]	_	_
28-26	4373-4381	response	organization[214]|abstract[220]	new[214]|giv[220]	_	_
28-27	4382-4386	with	organization[214]	new[214]	_	_
28-28	4387-4393	plasma	organization[214]|substance|abstract[222]|abstract[223]	new[214]|new|new[222]|new[223]	_	_
28-29	4394-4407	concentration	organization[214]|abstract[222]|abstract[223]	new[214]|new[222]|new[223]	_	_
28-30	4408-4422	quantification	organization[214]|abstract[223]	new[214]|new[223]	_	_
28-31	4423-4426	can	_	_	_	_
28-32	4427-4431	also	_	_	_	_
28-33	4432-4439	improve	_	_	_	_
28-34	4440-4447	patient	person|abstract[225]	giv|new[225]	_	_
28-35	4448-4456	outcomes	abstract[225]	new[225]	_	_
28-36	4457-4458	.	_	_	_	_

#Text=Close cooperation between oncologists , internists , pharmaceutics , and nurses should become the gold standard in the comprehensive clinical care of advanced NSCLC patients receiving TKIs .
29-1	4459-4464	Close	abstract[226]	new[226]	_	_
29-2	4465-4476	cooperation	abstract[226]	new[226]	_	_
29-3	4477-4484	between	abstract[226]	new[226]	_	_
29-4	4485-4496	oncologists	abstract[226]|person|person[228]	new[226]|giv|giv[228]	coref	29-4[228_0]
29-5	4497-4498	,	abstract[226]|person[228]	new[226]|giv[228]	_	_
29-6	4499-4509	internists	abstract[226]|person[228]|person	new[226]|giv[228]|new	_	_
29-7	4510-4511	,	abstract[226]|person[228]	new[226]|giv[228]	_	_
29-8	4512-4525	pharmaceutics	abstract[226]|person[228]|abstract	new[226]|giv[228]|new	_	_
29-9	4526-4527	,	abstract[226]|person[228]	new[226]|giv[228]	_	_
29-10	4528-4531	and	abstract[226]|person[228]	new[226]|giv[228]	_	_
29-11	4532-4538	nurses	abstract[226]|person[228]|person	new[226]|giv[228]|giv	_	_
29-12	4539-4545	should	_	_	_	_
29-13	4546-4552	become	_	_	_	_
29-14	4553-4556	the	_	_	_	_
29-15	4557-4561	gold	_	_	_	_
29-16	4562-4570	standard	_	_	_	_
29-17	4571-4573	in	_	_	_	_
29-18	4574-4577	the	abstract[232]	giv[232]	_	_
29-19	4578-4591	comprehensive	abstract[232]	giv[232]	_	_
29-20	4592-4600	clinical	abstract[232]	giv[232]	_	_
29-21	4601-4605	care	abstract[232]	giv[232]	_	_
29-22	4606-4608	of	abstract[232]	giv[232]	_	_
29-23	4609-4617	advanced	abstract[232]|person[234]	giv[232]|giv[234]	_	_
29-24	4618-4623	NSCLC	abstract[232]|abstract|person[234]	giv[232]|giv|giv[234]	_	_
29-25	4624-4632	patients	abstract[232]|person[234]	giv[232]|giv[234]	_	_
29-26	4633-4642	receiving	abstract[232]|person[234]	giv[232]|giv[234]	_	_
29-27	4643-4647	TKIs	abstract[232]|person[234]|abstract	giv[232]|giv[234]|new	_	_
29-28	4648-4649	.	_	_	_	_
